Avalon Healthcare Solutions Clinical Webinar

February 2017

BlueCross[®] BlueShield[®] of South Carolina and BlueChoice[®] HealthPlan of South Carolina are independent licensees of the Blue Cross and Blue Shield Association.

Avalon is an independent company that provides benefit management services on behalf of BlueCross BlueShield of South Carolina and BlueChoice Health Plan.

A HEALTHCARE SOLUTIONS

Agenda

- Welcome and Introductions
- Overview of Avalon Healthcare Solutions
- Scientific Laboratory Policy Development and Adherence
 - Avalon Prior Authorization Process
 - Avalon Claim Editor
- Provider Education
- Questions
- Quick Tips



Laboratory Marketplace

Harvard Medical School Study; "30% of Laboratory Tests Are Probably Un-necessary"

Study was led by investigators at Harvard Medical School and Beth Israel Deaconess Medical Center and reported online in the journal *PLOS ONE*, the large-scale analysis of 1.6 million results from 46 of medicine's 50 most commonly ordered lab tests found that, on average, 30 percent of all tests are probably unnecessary.



"It's not ordering more tests or fewer tests that we should be aiming for, it's ordering the right tests, however few or many that is," **Ramy Arnaout,** Harvard Medical School assistant professor of pathology

Harvard Medical School News, Nov 18, 2013 (Prescott); (http://hms.harvard.edu/news/unnecessary-testing-11-18-13)




Avalon Healthcare Solutions – Who we are

- Avalon is a clinical services and information technology company providing comprehensive diagnostic laboratory management services to health plans
- Avalon uses the latest evidence-based medicine to support robust laboratory-related scientific policies
- Avalon's program is a compliant and reliable extension of BlueCross BlueShield of South Carolina's medical management program

... and what we bring

- *Member Centric Focus Facilitation of access to high quality, appropriate and cost effective laboratory services*
- Scientific Policy Continuing evaluation of developments in clinical utility, resulting in creation of new or revision to existing scientific laboratory policies
- **Network** Dedicated to ensuring that patients receive the right test at the right time in the right setting
- **Technology** Complex claims editor for adherence to policies
- **Analytics** Enabling data-driven decision making in all facets of operations




Evolution of Avalon Scientific Laboratory Policy

Identification	Development	Specif	fic Effort	Peer Review	Progression
 Expert opinion Professional society guidelines Customer data and policies 	 Research issue Define medical necessity criteria Identify relevant procedure and diagnosis codes Determine need for prior- authorization Achieve congruence with client health plan 	 A standard template i Literature MNC is no than 5 yea publicatio years prefi Code over policies is and recon appropriat 	s utilized supporting greater ins from n, two erred lap within recognized ciled as	 Facilitate evaluation and discussion by Clinical Advisory Board ("CAB") Confirm coverage parameters, affirming explicit medical necessity criteria 	 Formalize policy approval and distribution Facilitate transfer of knowledge re: policy intent to Algorithm team Conduct no less than annual review to assess need for revision
 Laboratory Medical Director Associate Professor of Labore Pathology at the University Serves on the Medicare Ad 	ry at Harborview Medical Center, Se or at Northwest Hospital, Seattle oratory Medicine and Adjunct Associ	ate Professor of aboratory Tests	 Professional Practicing Professor Universit Serves or Current F Advisory 	g Medical and Clinical Molecular G r and Director of the Pharmacogen y School of Medicine n the American Medical Association Procedural Terminology (CPT) Advis Panel on Clinical Diagnostic Labora ests: Molecular Pathology, Molecu	omics Laboratory at Indiana n's (AMA's) Molecular Pathology sory committee and the Medicare atory Tests
 Timothy R. Hamill, MD Professional Experience: Professor emeritus and Ex-Vice Chair, Laboratory Medicine, University of California, San Francisco Prior Director, UCSF Clinical Laboratories Clinical Interests: Clinical Pathology, Hematopathology, and Laboratory Management 		 Brian R. Smith, MD Professional Experience: Professor and Chair of Laboratory Medicine, Professor of Biomedical Engineering, of Medicine (Hematology) and of Pediatrics at Yale School of Medicine Chief of Laboratories at Yale New Haven Hospital, New Haven, CT Clinical Interests: Hematopathology, Optimal utilization of state-of-the-art laboratory diagnostics 			



Laboratory Benefit Management



Avalon's services promote patients access to affordable, high-quality health care

AVALON 6

Laboratory Policies Subject to Prior Authorization, 2017

	BCR-ABL 1 Testing for Chronic			Cardiovascular Disease Risk
Alpha Thalassemia	Myeloid Leukemia	BRAF Gene Mutation Testing	BRCA	Assessment
		Familial Adenomatous		
		Polyposis and MUTYH-		FLT3 and NPM1 Mutation in
Chromosomal Microarray	Cytochrome P450	Associated Polyposis	Flow Cytometry	Acute Myeloid Leukemia
			Genetic Testing for 5	
Gene Expression Testing for	Gene Expression-based Assays		Fluorouracil Use in Cancer	Genetic Testing for CADASIL
Breast Cancer Prognosis	for Cancers of Unknown Primary	General Genetic Testing	Patients	Syndrome
Genetic Testing for Cardiac Ion	Genetic Testing for CHARGE	Genetic Testing for Cystic	Genetic Testing for Dilated	Genetic Testing for Duchenne
Channelopathies	Syndrome	Fibrosis	Cardiomyopathy	and Becker Muscular Dystrophy
				Genetic Testing for Germline
	Genetic Testing for			Mutations of the RET Proto-
	Facioscapulohumeral Muscular	Genetic Testing for Fanconi	Genetic Testing for FMR1	Oncogene in Medullary CA
Genetic Testing for Epilepsy	Dystrophy	Anemia	Mutations	Thyroid
			Genetic Testing for	
Genetic Testing for Hereditary	Genetic Testing for Li-Fraumeni	Genetic Testing for	Predisposition to Inherited	Genetic Testing for PTEN
Pancreatitis	Syndrome	Mitochondrial Disorders	Hypertrophic Cardiomyopathy	Hamartoma Tumor Syndrome
			JAK2 and MPL Mutation Analysis	
Genetic Testing for Rett		HIV Genotyping and	in Myeloproliferative	KRAS and BRAF Mutation
Syndrome	Hereditary Hemochromatosis	Phenotyping	Neoplasms	Analysis in Colorectal Cancer
		Molecular Analysis for Targeted		Molecular Panel Testing of
		Therapy for Non-small Cell Lung	Molecular Markers in Fine	Cancers to Identify Targeted
Liquid Biopsy	Lynch Syndrome	Cancer	Needle Aspirates of the Thyroid	Therapies
Multianalyte Assays with				
Algorithmic AnalysisLiver	Multigene Expression Assay for	Mutation Testing for Limb-	Non-invasive Prenatal	
Disease	Predicting Colon CA Recurrence	Girdle Muscular Dystrophies	Screening for Aneuploidy	PALB2 Mutation Testing
	Pharmacogenomic and			
PharmacogeneticTesting for	Metabolite Markers for	Pre-Implantation Genetic		Serum Tumor Markers for
Pain Managemen	Thiopurines	Testing	Prenatal Screening	Malignancies

Code Listings:

gs: <u>http://web.southcarolinablues.com/providers/providernews/2016providernews.aspx?article_id=922</u>

http://www.bluechoicesc.com/providers/news/currentnews.aspx?article_id=291

http://www.cam-policies.com



Avalon's Prior Authorization (PA) Program

- Avalon strives to ensure that health plan members promptly receive the correct test, at the appropriate time
- Avalon's PA program is structured to operate consistently within the standards developed by CMS, URAC and NCQA:
 - Pre-certification Review Process
 - Decision Making and Notification Timeframes
 - Peer to Peer Reviews
 - Health plan support of member appeals
- Program operations are overseen by Avalon Medical Director



- Coordination with Clinical Advisory Board as needed based on clinical area of expertise
- Staff are available from 8 a.m. to 8 p.m. Eastern Time, Monday–Friday
 - Relevant clinical information is needed
 - Template form is available



Avalon Prior Authorization Process


Preauthorization Requ	est Form			
URGENT (If checked, pleated)	ase provide anticipa	ted date of se	rvice below)	
Please fax completed form	n to 1-888-791-21	81		
Please attach supporting do this form should be placed of		-		r's protection,
Today's Date:				
Identification Number:	cation Number:		Group #	
Member's First and Last Name	r's First and Last Name:		Date of Service:	
Patient's Name (if different th	an above):		Date of Birth:	
			1	
Procedure Codes Requested:				
Diagnosis Codes:				
Diagnosis Codes: Ordering Provider Informatio	n:			
Diagnosis Codes: Ordering Provider Informatio NPI Number		or TIN		
Diagnosis Codes: Ordering Provider Informatio NPI Number		or TIN		
Procedure Codes Requested: Diagnosis Codes: Ordering Provider Informatio NPI Number Physician First and Last Name Address		or TIN		
Diagnosis Codes: Ordering Provider Informatio NPI Number Physician First and Last Name			Fax #	
Diagnosis Codes: Ordering Provider Informatio NPI Number Physician First and Last Name Address Contact Person	e		Fax #	
Diagnosis Codes: Ordering Provider Informatio NPI Number Physician First and Last Name: Address Contact Person Rendering Provider Data:	e		Fax #	
Diagnosis Codes: Ordering Provider Informatio NPI Number Physician First and Last Name Address Contact Person	e		Fax#	
Diagnosis Codes: Ordering Provider Informatio NPI Number Physician First and Last Name: Address Contact Person Rendering Provider Data: NPI Number(s)	e		Fax #	
Diagnosis Codes: Ordering Provider Informatio NPI Number Physician First and Last Name: Address Contact Person Rendering Provider Data:	e		Fax #	

Telephone:1-844-227-5769Fax:1-888-791-2181

- It is the responsibility of the ordering physician to obtain the authorization; however, a laboratory may do so if they have access to necessary clinical information
- Authorization requests accepted via phone or fax
 - Authorizations are in effect for 15 calendar days
 - Authorizations can be accepted/modified 15 calendar days post lab draw, PRIOR TO CLAIMS SUBMISSION, allowing for cascade of testing
- Approval decisions are communicated by phone or fax to the requesting & rendering provider
- Inability to authorize is communicated
 - By phone to the requesting provider (if urgent)
 - In writing to both the member and the requesting provider regardless of status within 1 business day
 - A peer-to-peer consult is offered within 5 days of notification to assist in sharing of additional and relevant information
 - The appeals process is communicated in the denial notification letter
- Lack of prior authorization results in
 - Rendering provider liability



Laboratory Benefit Management



Avalon's services promote patients access to affordable, high-quality health care




Laboratory Policies Not Subject to Prior Authorization, 2017

	Alphafetal Protein - L3 for Detection		Analysis of MGMT Promoter	Analysis of Proteomic Patterns for
Allergen Testing		ANA/ENA	Methylation for Malignant Gliomas	Early Detection of Cancer
Autoimmune neuropathy panel	Biochemical Markers of Alzheimers Disease	Lymph Node Metastasis Breast	Bone Turnover Markers Osteoporosis	Celiac Disease Testing
	Disease	Lymph Node Metastasis breast	Osteoporosis	Diagnosis and Management of
Cervical Cancer Screening	Charcot-Marie-Tooth disease (CMT)	Detection of Circulating Tumor Cells in Cancer Management	Detection of Down's Syndrome Using Maternal Serum Markers	Idiopathic Environmental Intolerance
Diagnosis of Vaginitis including		DNA-based Testing for Adolescent		Epithelial Cell Cytology in Breast
	DNA Ploidy Cell Analysis	Idiopathic Scoliosis	Ehlers Danlos/Marfan Syndrome	Cancer Risk Assessment
	Fecal Analysis of the Diagnosis of			Gamma Interferon Blood Test for Da
Erectile Dysfunction	Intestinal Dysbiosis	Fecal Calprotectin Testing	Ferritin	of Latent Tuberculosis
Gene Expression Profiling for UVEAL	Gene Expression Testing for Breast	Gene Expression Testing to Predict	General Genetic Testing, Germline	General Genetic Testing, Somatic
	Cancer Prognosis in male	Coronary Artery Disease	Disorders	Disorders
Genetic Cancer Susceptibility Panels		Genetic Testing for Cutaneous	Genetic Testing for Diagnosis of	Genetic Testing for Familial
using Next Generation Sequencing	trypsin Defiency	Malignant Melanoma Risk	Inherited Peripheral Neuropathies	Alzheimers
		Genetic Testing for Lipoprotein A		
	Genetic Testing for Lactase		Genetic Testing for Macular	Genetic Testing for Mental Health
Familial Hypercholesterolemia Genetic Testing for	Insufficiency Genetic Testing for Statin-induced	Treatment Genotyping for 9P21 Single	Degeneration	Conditions
-		Nucleotide Polymorphisms	Heart Transplant Rejection Tests	Heliobacter Pylori Testing
	Nyopatny	High Sensitivity to C-reactive		Tellobacter Pyloti Testing
Hemoglobin A1c	Hepatitis C	Protein and Tonometry	HIV Tropism	Homocysteine Testing
	Identification of Micro-organisms by			
Homocystinuria	Nucleic Probes	IGT	Immune Cell Function Assay	Immuno-histo chemistry
			KIF6 Genotyping for Predicting	
		Invitro Chemo-resistance and	Cardiovascular Risk and/or	KRAS Mutation Analysis in Non Sma
InflammaDry	Intracellular Micronutrient Analysis		Effectiveness of Statin Therapy	Cell Lung Cancer
	Measurement of Lipoprotein,	Measurement of Long Chain Omega	Measurement of Serum Antibodies	Measurement of Serum
			incusurement of serum / incloodies	
	Associated Phospholipase A2	3 Fatty Acids	to Infliximab Adalimumab	Intermediate Density Lipoproteins
Measurement of Thromboxane	Associated Phospholipase A2 MUC16 (CA-125) Expression in	3 Fatty Acids	to Infliximab Adalimumab Oral Screening Lesion Identification	Intermediate Density Lipoproteins
Measurement of Thromboxane Metabolites for ASA Resistance	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer		to Infliximab Adalimumab	Intermediate Density Lipoproteins Paraneoplastic antibody panel
Measurement of Thromboxane Metabolites for ASA Resistance	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for	3 Fatty Acids Nerve Fiber Density Testing	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children &
Measurement of Thromboxane Metabolites for ASA Resistance	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children & Adolescents
Measurement of Thromboxane Metabolites for ASA Resistance Pathfinder TG Molecular Testing	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for HIV-1 Infection	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing Proteomics-Based Testing related to	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults Quantitative Assay for Measurement	Paraneoplastic antibody panel Preventive Screening in Children & Adolescents tRapid Flu Test in the Outpatient
Measurement of Thromboxane Metabolites for ASA Resistance Pathfinder TG Molecular Testing Prostate Biopsies	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for HIV-1 Infection Prostate Cancer Screening	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing Proteomics-Based Testing related to Ovarian Cancer	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults Quantitative Assay for Measurement of Serum HER2	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children & Adolescents
Measurement of Thromboxane Metabolites for ASA Resistance Pathfinder TG Molecular Testing Prostate Biopsies	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for HIV-1 Infection Prostate Cancer Screening Serum Antibodies for the Diagnosis	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing Proteomics-Based Testing related to Ovarian Cancer Serum Biomarker Human Epididymis	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults Quantitative Assay for Measurement of Serum HER2 Serum Biomarker Tests for Multiple	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children & Adolescents tRapid Flu Test in the Outpatient Setting
Measurement of Thromboxane Metabolites for ASA Resistance Pathfinder TG Molecular Testing Prostate Biopsies	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for HIV-1 Infection Prostate Cancer Screening	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing Proteomics-Based Testing related to Ovarian Cancer	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults Quantitative Assay for Measurement of Serum HER2	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children & Adolescents Rapid Flu Test in the Outpatient Setting ST2 Assay for CHF
Measurement of Thromboxane Metabolites for ASA Resistance Pathfinder TG Molecular Testing Prostate Biopsies	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for HIV-1 Infection Prostate Cancer Screening Serum Antibodies for the Diagnosis	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing Proteomics-Based Testing related to Ovarian Cancer Serum Biomarker Human Epididymis	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults Quantitative Assay for Measurement of Serum HER2 Serum Biomarker Tests for Multiple Sclerosis	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children & Adolescents tRapid Flu Test in the Outpatient Setting ST2 Assay for CHF Use of Common Genetic Variants to
Measurement of Thromboxane Metabolites for ASA Resistance Pathfinder TG Molecular Testing Prostate Biopsies Salivary Hormone Testing	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for HIV-1 Infection Prostate Cancer Screening Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing Proteomics-Based Testing related to Ovarian Cancer Serum Biomarker Human Epididymis	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults Quantitative Assay for Measurement of Serum HER2 Serum Biomarker Tests for Multiple	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children & Adolescents Rapid Flu Test in the Outpatient Setting ST2 Assay for CHF
Measurement of Thromboxane Metabolites for ASA Resistance Pathfinder TG Molecular Testing Prostate Biopsies Salivary Hormone Testing	Associated Phospholipase A2 MUC16 (CA-125) Expression in Ovarian Cancer Plasma HIV 1 RNA Quantification for HIV-1 Infection Prostate Cancer Screening Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease	3 Fatty Acids Nerve Fiber Density Testing Pre-Operative Testing Proteomics-Based Testing related to Ovarian Cancer Serum Biomarker Human Epididymis Protein 4 (HE4)	to Infliximab Adalimumab Oral Screening Lesion Identification Systems and Genetic Testing Preventative Screening in Adults Quantitative Assay for Measurement of Serum HER2 Serum Biomarker Tests for Multiple Sclerosis Urinary Tumor Markers for Bladder	Intermediate Density Lipoproteins Paraneoplastic antibody panel Preventive Screening in Children & Adolescents tRapid Flu Test in the Outpatient Setting ST2 Assay for CHF Use of Common Genetic Variants to Predict Risk of non-Familial Breast



Claim Editor Example

• A subset of the criteria from the Cervical Cancer Screening policy



frequency of every 3 years.

Patient 21-29 years of age, testing for high-risk strains of HPV meets coverage criteria when the cytology from a Pap smear is positive for atypical squamous cells of undetermined significance (ASCUS).



Avalon Claim Editor: Edit Types Defined

• Claim Editor rules correspond to the criteria as defined in the health plan's policy.

Rule	Definition
Experimental & Investigational	Procedure is not covered under the member's benefit due to the experimental and investigational exclusion
Demographics	Limitations based on patient age or gender
Procedure Units	Within and across claim for a Date of Service
Units/Period of Time	Maximum allowable units within a defined period of time
Time between Procedures	Minimum time required before a second procedure is medically necessary
Rendering Provider Limitations	Providers/procedures not permitted in combination
Diagnosis Constraints and Allowances	Procedure and Diagnosis required or prohibited combinations
Diagnosis Does Not Support Test Requested	Procedure was not appropriate for the clinical situation





Provider Education

Avalon has provided many avenues for ordering provider education


- Conducting network webinars
- On-demand Educational Policy Videos available via the BlueCross My Insurance ManagerSM website
- Requiring Avalon contracted laboratory network providers to educate ordering physicians, as per existing referral practice patterns
- BlueCross has issued email blasts, website notification, and newsletter communication addressing program requirements and scope
- Upcoming Clinical Webinars: 2/7, 2/9 & 2/23



Avalon Claim Editor: Trial Claim Advice Tool

The Trial Claim Advice Tool allows the user to simulate the Claim Editor processing of specific procedure codes and diagnoses

NOTE: Results may not be the final adjudication advice due to the application of member benefits and business rules





Provider Education Videos





Provider Home

Education Video Library

BCBSSC 2017 Prior Authorization List is now available!

NEW – Policy Education Video Library

Avalon's Clinical Advisory Board Chair, Dr. Geoffrey Baird, provides an understanding of the rationale

for policies. The "Introduction to Laboratory Testing Policy" video provides the fundamentals of

our policy development. The following policies are also included in our education video library:

- Allergens
- Cardiovascular and Lipid
- Cervical Cancer Screening
- Hemoglobin A1c
- Rapid Influenza
- Vitamin B12
- Vitamin D

Please follow the Link: Policy Education Video Library



AVALON | 16

Avalon Claim Editor Example Decisions

83036 Glycosylated hemoglobin test

CAM133 - Hemoglobin A1c

Insufficient time between procedures

Procedure was not appropriate for the clinical situation

86003 Allergen specific ige

CAM051 - Allergen Testing

Procedure was not appropriate for the clinical situation

Maximum allowable units was exceeded

Too many procedures within the required period of time

82306 Vitamin d 25 hydroxy

CAM126 - Vitamin D

Procedure was not appropriate for the clinical situation

Too many procedures within the required period of time

Maximum allowable units was exceeded

82607 Vitamin b-12

CAM130 - Vitamin B12 and Methylmalonic Acid

Procedure was not appropriate for the clinical situation

Insufficient time between procedures



Avalon Healthcare Solutions: Quick Tips

- Remember to send patients to in-network laboratories. Refer to provider directories or link below:
 - http://web.southcarolinablues.com/providers/providernews/2016providernews.aspx?article_id=921
- Review the Lab Prior Authorization Matrix to determine codes that require prior authorization:
 - http://web.southcarolinablues.com/providers/providernews/2016providernews.aspx?article_id=922
 - http://www.bluechoicesc.com/providers/news/currentnews.aspx?article_id=291
- Utilize the Avalon Trial Claim Advice Tool in My Insurance Manager to see how the Claim Editor will review codes and what medical policies may apply
- Refer to BlueCross and BlueChoice[®] HealthPlan websites for bulletins, guides, presentations and other resources
 - web.southcarolinablues.com/providers/educationcenter.aspx
- For additional questions please contact:
 - Avalon Provider Services at 1-855-895-1676
 - BlueCross Provider Education at:
 - provider.eduction@bcbcsc.com or by calling 803-264-4730

